Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker Corporation (Nasdaq: BRKR) reported Q3 2022 revenue of $638.9 million, a 4.9% increase year-over-year, with organic growth at 12.7%. GAAP EPS rose to $0.59, and non-GAAP EPS increased 4.8% to $0.66. The company raised its FY 2022 guidance for organic revenue growth to 8%-10%, up from 7%-9%, while non-GAAP operating margin guidance was also increased to 60-90 bps. Additionally, Bruker's backlog and high-demand products contributed to a strong financial outlook despite currency translation headwinds of 8%.
Bruker Corporation (Nasdaq: BRKR) will release its Q3 2022 financial results on November 3, 2022, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and business trends. Investors can participate via webcast or telephone, with an option to pre-register for expedited entry. A replay of the call will be available until December 3, 2022. Bruker focuses on providing high-performance scientific instruments and solutions, enhancing research in life sciences and diagnostics.
Bruker Corporation (NASDAQ: BRKR) has launched the nanoElute® 2 nano-LC system and updated software for MetaboScape® and TASQ® at IMSC 2022. The new nanoElute® 2 enhances single-cell proteomics with improved chromatography performance and user interface. MetaboScape 2023 introduces advanced metabolic profiling features and quality assessment tools. The MALDI HiPLEX-IHC workflow enables multiplex imaging for protein targets, enhancing spatial localization. These innovations support research in proteomics and protein interactions, significantly advancing capabilities in the scientific community.
Bruker Corporation has unveiled groundbreaking advancements in NMR technology at the ICMRBS 2022 Conference. Their new 8 mm 15N TROSY Cryoprobe improves sensitivity for studying larger proteins and disordered proteins, doubling the sensitivity of earlier models. Additionally, the 160 kHz Ultra-fast spinning MAS probe enhances solid-state NMR analysis, facilitating research on neurodegenerative diseases. Bruker also announced the installation of the 1.2 GHz Avance™ NMR at the University of Lille, expanding research capabilities in structural biology across France.
Bruker Corporation (Nasdaq: BRKR) announced a quarterly cash dividend of $0.05 per share, payable on September 16, 2022, to shareholders of record as of September 1, 2022. This dividend reflects the company's commitment to returning value to its investors. Bruker is dedicated to enabling scientific breakthroughs and innovative applications across various sectors, including life sciences and diagnostics, enhancing productivity and customer success. For additional details, visit www.bruker.com.
Bruker Corporation (Nasdaq: BRKR) reported Q2 2022 revenues of $588.4 million, up 3.1% year-over-year, with organic growth of 8.8%. GAAP diluted EPS was $0.33, down from $0.38 in Q2 2021, while non-GAAP diluted EPS rose 2.3% to $0.45. For FY 2022, the company maintains its organic revenue growth guidance of 7% to 9%, despite adjusting reported revenue growth expectations to 2.5% to 4.5% due to currency headwinds. Non-GAAP operating margin is projected to expand by 30 to 60 basis points, with EPS expected between $2.29 and $2.33, marking a 9% to 11% increase year-over-year.
Bruker Corporation (Nasdaq: BRKR) will announce its second quarter 2022 financial results on August 3, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern Time to discuss results and business trends. Investors can participate via webcast on Bruker's website or by telephone. Pre-registration is available to expedite entry. A replay of the call will be accessible from one hour after its conclusion until September 3, 2022. Bruker specializes in high-performance scientific instruments and solutions to enhance research and diagnostics.
Acuamark Diagnostics announced the closing of an $11.3 million Series A funding round led by Claudio Del Vecchio and joined by Bruker Corporation. The funds will further develop AcuamarkDx's technology for early cancer detection, aiming for more reliable and cost-effective solutions. Del Vecchio joins the board, bringing extensive experience from Luxottica and Brooks Brothers. The company plans to scale sample collections and enhance its infrastructure to optimize clinical assessments.
Bruker Corporation has received three new orders for its Ascend Evo 1.0 GHz NMR magnets, designed for structural biology and clinical research in single-story laboratories. These orders are from the
Bruker Corporation (Nasdaq: BRKR) has launched PhenoRisk PACS™ RuO, a research-use-only NMR test for analyzing blood samples from Long COVID patients. Developed in collaboration with the Australian National Phenome Center, this innovative test identifies early-stage risk factors and monitors recovery through a 20-minute assessment of biological markers. It aims to enhance understanding of Long COVID's impact on various organs, potentially aiding clinical research and treatment. The test offers significant advancements in the assessment of metabolic and proteomic biomarkers linked to SARS-CoV-2.
FAQ
What is the current stock price of Bruker Corporation (BRKR)?
What is the market cap of Bruker Corporation (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
